---
layout: default
title: Publications
page_type: 'left_sidebar'
---

<!-- Header -->
	<div id="header">

		<!-- Inner -->
			<div class="inner">
				<header>
					<h1>Selected publications</h1>
				</header>
			</div>

		{% include navigation.html %}

	</div>

<!-- Main -->
	<div class="wrapper style1">

		<div class="container">
			<div class="row gtr-200">
				
				{% include subjects_sidebar.html %}

				<div class="col-8 col-12-mobile imp-mobile" id="content">
					<article id="main">
						<header>
							<h2><a href="#">Epidemiology</a></h2>
						</header>
						<p> Kerr, S, Robertson, C, Hillman, S, Grange, Z et al. <br> <a href = 'https://doi.org/10.1016/j.lanepe.2022.100533 ' target="_blank"> 
							Letter: Severity of Omicron BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland</a>.<br> 
							International Journal of Epidemiology.
						<p> Kerr S, Bedston S, Bradley DT, Joy M, Lowthian E, Mulholland RM et al. <br> <a href = 'https://doi.org/10.1093/ije/dyac199' target="_blank"> 
							Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled 
							target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales</a>.<br> 
							International Journal of Epidemiology.
						<p> Agrawal A, Bedston S, McCowan C, Oke J, Patterson L, Robertson C et al. <br> <a href = 'https://doi.org/10.1016/S0140-6736(22)01656-7' target="_blank"> 
							Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 
							30 million individuals in England, Northern Ireland, Scotland, and Wales</a>.<br> 
							The Lancet.</p>	
						<p> Simpson CR, Kerr S, Katikireddi S.V, McGowan C, et.al, <br> <a href = 'https://doi.org/10.1038/s41467-022-32264-6' target="_blank"> 
							Second-dose Oxford-AstraZeneca and Pfizer-BioNTech vaccines and blood clotting and bleeding events in Scotland</a>.<br> 
							Nature Communications.</p>				
						<p> PHOSP-COVID Collaborative Group, <br> <a href = 'https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00127-8/fulltext' target="_blank"> 
							Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective 
							observational study</a>.<br> 
							The Lancet Respiratory Medicine. </p>
						<p> Kerr S, Joy M, Torabi F, Bedston S, Akbari A, Agrawal U et al, <br> 
							<a href = 'https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003927' target="_blank"> First dose ChAdOx1 and 
							BNT162b2 COVID-19 vaccinations and  cerebral venous sinus thrombosis: A pooled self-controlled case series study of 12 million individuals 
							in England, Scotland and Wales</a>.<br> 
							PLOS medicine.</p>
						<p> Agrawal U, Katikireddi SV, McCowan C, Mulholland RH, Azcoaga-Lorenzo A, Amele S, Fagbamigbe et al <br> 
							<a href = 'https://doi.org/10.1016/S2213-2600(21)00380-5' target="_blank"> COVID-19 hospital admissions and deaths after 
							BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study </a>.<br> 
							The Lancet Respiratory Medicine.</p>
						<p> Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C, <br> Severity of Omicron variant of concern and vaccine effectiveness 
							against symptomatic disease: national cohort with nested test negative design study in Scotland - 
							<a href = 'https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness-' target="_blank">preprint </a>,  
							<a href = 'https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00141-4/fulltext' target="_blank">publication - Lancet Infectious Diseases</a>.</p>
						<p> Ting S, P Jiafeng, Katikireddi V, McCowan C, Kerr S, Agrawal U et al, <br>
							<a href = 'https://doi.org/10.1016/S2213-2600(21)00491-4' target="_blank">  Risk of COVID-19 hospital admission among children aged 5–17 
							years with asthma in Scotland: a national incident cohort study</a>.<br> 
							The Lancet Respiratory Medicine.</p>	
						<p> Simpson CR, Kerr S, Shi T, Vasileiou E, Moore E, McCowan C et al, <br> 
							<a href = 'https://thorax.bmj.com/content/early/2021/11/14/thoraxjnl-2021-217580' target="_blank"> External validation of the QCovid risk 
							prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland</a>.<br> 
							Thorax.</p>
						<p> Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E et al, <br>  
							<a href = 'https://doi.org/10.1038/s41591-021-01408-4' target="_blank">  First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and 
							thrombocytopenic, thromboembolic and hemorrhagic events in Scotland</a>.<br>
							Nature Medicine. </p>
						<p> PHOSP-COVID Collaborative Group, <br>  
							<a href = 'https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00383-0/fulltext' target="_blank"> Physical, cognitive and mental 
							health impacts of COVID-19 following hospitalisation -- a multi-centre prospective cohort study</a>.<br>  
							The Lancet Respiratory Medicine. </p>
						<p>  Vasileiou E, Simpson CR, Robertson C, Shi T, Kerr S, et al, <br>  
							<a href = 'https://doi.org/10.1016/S0140-6736(21)00677-2' target="_blank"> Interim findings from first-dose mass COVID-19 
							vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study</a>.<br> 
							The Lancet.</p>
					</article>
				</div>
			</div>
		</div>

	</div>
